FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

Healio Rheumatology—April 6, 2018

Healio Rheumatology reported that the FDA rejected the approval of a biopharmaceutical company’s biologics license applications.

HSS rheumatologist Allan Gibofsky, MD, noted that this rejection demonstrates the careful scrutiny that the FDA applies to both the manufacturing process and quality control of biologic products.

"While I don’t think this rejection will ‘shake’ consumer or prescriber confidence in biosimilars, I do think it will make both stakeholders look carefully at the reputation of the manufacturer and, where appropriate, any manufacturing partner they may have," said Dr. Gibofsky.

Read the full article at healio.com [registration required].

 

 

Need Help Finding a Physician?

Call us toll-free at:
+1.877.606.1555

Conditions & Treatments

adult child
Select A Body Part
Conditions: Adult head Conditions: Adult spine Conditions: Adult shoulder Conditions: Adult elbow Conditions: Adult hand Conditions: Adult hip Conditions: Adult knee Conditions: Adult ankle Conditions: Adult head Conditions: Adult full body Conditions: Child spine Conditions: Child elbow Conditions: Child hip Conditions: Child hand Conditions: Child knee Conditions: Child ankle Conditions: Child full body


Conditions A-Z
A B C D E F G H I
J K L M N O P Q R
S T U V W X Y Z
SEE ALL

Media Contacts

Tracy Hickenbottom
Monique Irons
Sherry Randolph

212.606.1197
mediarelations@hss.edu

Social Media Contacts

Andrew Worob
Otis Gamboa
socialmediacontact@hss.edu